This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
O'Brien S , Radich JP , Abboud CN , Akhtari M , Altman JK , Berman E , DeAngelo DJ , Deininger M , Devine S , Fathi AT , Gotlib J , Jagasia M , Kropf P , Moore JO , Pallera A , Pinilla-Ibarz J , Reddy VV , Shah NP , Smith BD , Snyder DS , Wetzler M , Gregory K , Sundar H
Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines
Journal of the National Comprehensive Cancer Network. 2013 Nov;11(11) :1327-1340
AbstractThe 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level <= 10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).
NotesO'Brien, Susan Radich, Jerald P. Abboud, Camille N. Akhtari, Mojtaba Altman, Jessica K. Berman, Ellin DeAngelo, Daniel J. Deininger, Michael Devine, Steven Fathi, Amir T. Gotlib, Jason Jagasia, Madan Kropf, Patricia Moore, Joseph O. Pallera, Arnel Pinilla-Ibarz, Javier Reddy, Vishnu Vb. Shah, Neil P. Smith, B. Douglas Snyder, David S. Wetzler, Meir Gregory, Kristina Sundar, Hema